drugset
drugset / Trial / NCT04865536

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

NCT04865536 ↗

Phase 1 Completed 28 enrolled Global Alliance for TB Drug Development
RandomizedParallel-groupTriple-blindTreatment

Summary

A Phase 1, Partially-Blinded, Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Include A Single Dose Food-Effect Study to Evaluate the Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Timeline

Start
2021-02-03
Primary completion
2021-05-17
Completion
2022-05-17

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator TBI-223 Small molecule 1800 mg —
Comparator TBI-223 Small molecule 2400 mg —

Indications

pulmonary tuberculosis